Collegium Q2 revenue up 7% to $145.3M; adjusted EPS $1.62; Ironshore acquisition on track

COLLEGIUM PHARMACEUTICAL, INC

2024-Q2 EPS reported $1.24 revenue$290,199,000

Net revenue $145.3M (+7% YoY); Belbuca record $52.2M (+21% YoY); GAAP net income $19.6M (+51% YoY).
Non-GAAP adjusted net income $64.0M, adjusted EPS $1.62; Adjusted EBITDA $96.0M (+12% YoY).
Acquiring Ironshore Therapeutics for $525M cash + up to $25M milestone; expected close Q3'24; funded by new $646M term loan.
Reaffirmed FY2024 guidance: Product Revenue $580-595M, Adjusted EBITDA $380-395M.
Pediatric exclusivity for Nucynta franchise extended to Jan 2027 (Nucynta) and Dec 2025 (Nucynta ER).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.